OncWeekly

G6PD inhibition leads to oxidative stress and cell death in tumors, boosting the efficacy of immunotherapies. #Oncology #CancerTreatment #G6PD - buff.ly/3yA5eN8

Patients with low G6PD expression have better outcomes with ICIs, suggesting a new therapeutic strategy. #CancerResearch #Immunotherapy #Oncology #LungCancer - buff.ly/3yA5eN8

SRS/FSR for CSM yields high CNN recovery rates and long-term tumor control, with SRS showing quicker improvements. #Oncology #CancerCare #RadiationOncology #OncWeekly - buff.ly/3WMsbWG

ML classifiers' accuracy in predicting PCR in breast cancer evaluated. #Oncology #CancerResearch #BreastCancer #MachineLearning #PrecisionOncology #OncWeekly - buff.ly/4bWDWhL

Study shows low G6PD expression in tumors improves immune response and outcomes of immune checkpoint inhibitors. #CancerTreatment #Oncology #Immunotherapy #LungCancer #Melanoma - buff.ly/3yA5eN8

Upfront resection in elderly glioblastoma patients significantly improves survival rates. Key finding for treatment approaches. #CancerResearch #Glioblastoma #Oncology - buff.ly/3WywBAH

Study: SRS/FSR for CSM shows significant CNNs recovery and excellent long-term radiological control. #Oncology #CancerResearch #Radiology #OncWeekly - buff.ly/3WMsbWG

Upfront resection improves survival in elderly glioblastoma patients, study reveals. buff.ly/3WywBAH

Study shows COX-2 overexpression is linked to worse prognosis in breast cancer, correlated with TNM staging and histological grading. #BreastCancer #Oncology #COX2 - buff.ly/4d8ApOG

G6PD inhibition triggers immunogenic cell death, enhancing immunotherapy effectiveness against tumors. #CancerResearch #Immunotherapy #G6PD #Oncology #LungCancer #Melanoma - buff.ly/3yA5eN8

FDA reviews Immorta Bio's Senovax IND application for NSCLC. Potential breakthrough in lung cancer treatment on the horizon. #NSCLC #LungCancer #OncologyNews - buff.ly/4cglDUS

Study compares ML classifiers for predicting PCR in breast cancer. #Oncology #CancerResearch #BreastCancer #MachineLearning #ClinicalTrials #OncWeekly - buff.ly/4bWDWhL

SRS/FSR treatments for CSM lead to effective cranial nerve recovery and sustained tumor control. #CancerTreatment #Oncology #ClinicalTrials #OncWeekly - @ElbazTehila - buff.ly/3WMsbWG

Can ML improve PCR prediction in BC? Dive into the latest comparison of classifiers and find out! #Oncology #CancerResearch #BreastCancer #AIinMedicine #OncWeekly - buff.ly/4bWDWhL

ICI + Antiangio-Ab leads in safety for NSCLC post-ICI failure. #Oncology #CancerResearch #OncWeekly - buff.ly/4cN0iDi

Study highlights potential of ARS model in LUAD treatment and prognosis. #Cancer #LungCancer #ClinicalTrials #OncWeekly buff.ly/3W8nGpm

Improved survival in elderly glioblastoma patients through upfront resection. #CancerResearch #Glioblastoma #Oncology - buff.ly/3WywBAH

Study: TKI + Chemo superior for PFS, ORR; ICI + TKI for OS in NSCLC post-ICI failure. #Cancer #OncWeekly - buff.ly/4cN0iDi

Elevated CKS1B in LUAD cells promotes growth and invasion. #CancerResearch #Oncology #ClinicalTrials #OncWeekly buff.ly/3W8nGpm

CLINICAL TRIAL - Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) buff.ly/3WurZv8